ストックスクリーナーアプリを入手
97.17
1.61%
-1.59
アフターアワーズ：
97.17
前日終値:
$98.76
開ける：
$100.04
24時間の取引高:
621.84K
Relative Volume:
0.59
時価総額：
$6.76B
収益：
$434.41M
当期純損益:
$-128.05M
株価収益率:
-46.05
EPS:
-2.11
ネットキャッシュフロー:
$-250.52M
1週間 パフォーマンス:
-7.14%
1か月 パフォーマンス:
+18.43%
6か月 パフォーマンス:
-3.63%
1年 パフォーマンス:
-10.31%
1日の値動き範囲:
$97.08
$101.34
1週間の範囲:
$97.08
$104.78
52週間の値動き範囲:
$73.04
$121.90
Blueprint Medicines Corp Stock (BPMC) Company Profile
名前
Blueprint Medicines Corp
セクター
電話
617-374-7580
住所
45 SIDNEY STREET, CAMBRIDGE, MA
BPMC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
BPMC
Blueprint Medicines Corp
|
97.17 | 6.76B | 434.41M | -128.05M | -250.52M | -2.11 |
|
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
Blueprint Medicines Corp Stock (BPMC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-03-20 | 再開されました | Morgan Stanley | Equal-Weight |
| 2025-03-18 | 開始されました | Wolfe Research | Outperform |
| 2025-03-17 | 開始されました | Jefferies | Buy |
| 2025-03-07 | 開始されました | Scotiabank | Sector Outperform |
| 2024-11-14 | 開始されました | JP Morgan | Overweight |
| 2024-10-24 | 開始されました | UBS | Neutral |
| 2024-05-14 | 開始されました | Stephens | Overweight |
| 2024-05-06 | アップグレード | Leerink Partners | Underperform → Market Perform |
| 2023-10-27 | アップグレード | Oppenheimer | Perform → Outperform |
| 2023-08-21 | 繰り返されました | Needham | Buy |
| 2023-07-31 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-06-05 | ダウングレード | SVB Securities | Market Perform → Underperform |
| 2023-01-03 | アップグレード | Wells Fargo | Underweight → Equal Weight |
| 2022-12-14 | 開始されました | Needham | Buy |
| 2022-11-02 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-09-14 | 開始されました | Berenberg | Buy |
| 2022-07-08 | 開始されました | Oppenheimer | Outperform |
| 2022-06-27 | 開始されました | Wells Fargo | Underweight |
| 2022-06-10 | ダウングレード | Citigroup | Neutral → Sell |
| 2022-06-01 | アップグレード | Jefferies | Hold → Buy |
| 2022-03-01 | 開始されました | Citigroup | Neutral |
| 2022-02-17 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2022-01-25 | アップグレード | Stifel | Hold → Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-09-30 | 再開されました | Stifel | Hold |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-03-31 | 開始されました | Credit Suisse | Neutral |
| 2020-12-03 | 開始されました | Stifel | Hold |
| 2020-11-02 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-11-02 | ダウングレード | Jefferies | Buy → Hold |
| 2020-10-30 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2020-07-15 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Equal Weight |
| 2020-03-17 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-28 | 開始されました | BMO Capital Markets | Market Perform |
| 2020-01-27 | 開始されました | BMO Capital Markets | Market Perform |
| 2019-11-06 | アップグレード | Raymond James | Outperform → Strong Buy |
| 2019-10-22 | 開始されました | JMP Securities | Mkt Outperform |
| 2019-10-03 | 開始されました | H.C. Wainwright | Buy |
| 2019-09-12 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2019-08-29 | 開始されました | Piper Jaffray | Neutral |
| 2019-08-15 | 再開されました | Raymond James | Mkt Perform |
| 2019-07-18 | 開始されました | Deutsche Bank | Buy |
| 2019-05-23 | 再開されました | Goldman | Buy |
| 2019-04-03 | 開始されました | Morgan Stanley | Overweight |
| 2018-09-25 | 開始されました | Leerink Partners | Outperform |
| 2017-12-11 | 繰り返されました | Goldman | Buy |
すべてを表示
Blueprint Medicines Corp (BPMC) 最新ニュース
Shares Of Blueprint Medicines Corp (NASDAQ: BPMC): Are They Overvalued Compared To Others? - Stocksregister
Insider Sell: Christina Rossi Sells Shares of Blueprint Medicines Corp (BPMC) - GuruFocus
Blueprint Medicines Executives Sell Shares - TradingView
Blueprint Medicines at The Citizens JMP Life Sciences Conference: Strategic Insights - Investing.com
Amarin (NASDAQ:AMRN) & Blueprint Medicines (NASDAQ:BPMC) Financial Survey - Defense World
Blueprint Medicines (NASDAQ:BPMC) Upgraded at StockNews.com - Defense World
Blueprint Medicines’ (BPMC) Buy Rating Reiterated at HC Wainwright - Defense World
Blueprint Medicines First Quarter 2025 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Blueprint Medicines Corporation (NASDAQ:BPMC) Q1 2025 Earnings Call Transcript - Insider Monkey
Blueprint Medicines Corp (BPMC) Stock: A Year of Highs and Lows in the Market - investchronicle.com
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Med - GuruFocus
Blueprint Medicines Corp (BPMC) Performance and Fundamentals Dashboard tells a completely different story - Sete News
BPMC: HC Wainwright & Co. Reiterates Buy Rating on Blueprint Medicines | BPMC Stock News - GuruFocus
Blueprint Medicines Corp (BPMC) Q1 2025 Earnings Call Highlights: Strong AYVAKIT Revenue Growth ... - Yahoo Finance
Blueprint Medicines reports Q1 EPS 1c, consensus (44c) - TipRanks
Blueprint Medicines Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Blueprint Medicines Q1 2025 beats EPS, stock rises - Investing.com India
Blueprint Medicines Corp. Reports Strong Earnings Growth - TipRanks
Blueprint Medicines (BPMC) Faces Q1 Revenue Miss, Focuses on Str - GuruFocus
Blueprint Medicines Corp Reports Q1 2025 Earnings: EPS of -$0.56 - GuruFocus
Earnings call transcript: Blueprint Medicines Q1 2025 beats EPS, stock rises By Investing.com - Investing.com South Africa
Blueprint Medicines Corp (NASDAQ: BPMC) Stock Jumping 14.80% Over A Month – Any Room For Its Value To Rise? - Marketing Sentinel
Predicting Blueprint Medicines Corp’s (BPMC) earnings for the current quarter - uspostnews.com
Blueprint Medicines Corp reports results for the quarter ended March 31Earnings Summary - TradingView
Blueprint Medicines Q1 2025 slides: AYVAKIT revenue surges 61%, guidance raised - Investing.com India
Blueprint Medicines: Q1 Earnings Snapshot - marketscreener.com
Blueprint Medicines Corp earnings beat by $0.50, revenue fell short of estimates - Investing.com
Blueprint Medicines Reports First Quarter 2025 Results - TradingView
Blueprint Medicines Reports First Quarter 2025 Results and Raises AYVAKIT®/AYVAKYT® (avapritinib) Full Year Revenue Guidance - PR Newswire
Blueprint Medicines patents new EGFR mutant inhibitors for NSCLC - BioWorld MedTech
Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $130.00 by Analysts at Needham & Company LLC - Defense World
Needham Adjusts Price Target for Blueprint Medicines (BPMC) Ahea - GuruFocus
What Analysts Are Saying About Blueprint Medicines Stock - Benzinga
Blueprint Medicines stock target cut to $130 at Needham - Investing.com
Press Release Distribution & PR Platform - ACCESS Newswire
Envestnet Asset Management Inc. Buys 3,723 Shares of Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Announces Q1 2025 Earnings Date: Key Biotech Updates Coming May 1 - Stock Titan
Blueprint Medicines Corp (BPMC) is looking forward to a strong quarter - Sete News
Blueprint Medicines (BPMC) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
Blueprint Medicines (BPMC) to Release Earnings on Thursday - Defense World
Blueprint Medicines Corporation (BPMC): Among Takeover Rumors Hedge Funds Are Buying - Insider Monkey
Wells Fargo & Company MN Cuts Stock Holdings in Blueprint Medicines Co. (NASDAQ:BPMC) - Defense World
Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by LPL Financial LLC - Defense World
BPMC stock rated an Equal-weight by Morgan Stanley - knoxdaily.com
Wedbush Decreases Earnings Estimates for Blueprint Medicines - Defense World
What is Wedbush’s Forecast for BPMC Q3 Earnings? - Defense World
Wedbush Reaffirms “Outperform” Rating for Blueprint Medicines (NASDAQ:BPMC) - Defense World
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Blueprint Medicines (BPMC) - The Globe and Mail
Blueprint Medicines Co. (NASDAQ:BPMC) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Blueprint Medicines Corp (BPMC) 財務データ
収益
当期純利益
現金流量
EPS
0.84%
0.15%
大文字化:
|
ボリューム (24 時間):